This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Ed Yaworski
Chief Technology Officer at Genevant Sciences Corp.


Ed Yaworski is the Chief Technology Officer at Genevant Sciences Corp. where he leads the development of nucleic acid therapeutics utilizing Genevant’s proprietary lipid nanoparticle (LNP) technology or next generation ligand conjugate technology. He has 30 years of experience in the pharmaceutical industry including 20 years working with delivery systems for nucleic acids, during which he helped advance more than a dozen products into clinical trials in the areas of oncology, metabolic disorders, and infectious diseases. Ed is an expert in LNP pharmaceutical development, scale-up, and manufacturing. He is a pioneer of LNP formulation methods and compositions and is an inventor of Genevant’s leading LNP delivery technology. Ed holds an MSc in Chemistry from the University of Manitoba.

Agenda Sessions

  • Workshop Leader’s Welcome and Opening Remarks

  • Expanding Therapeutic Applications of mRNA Technology Through Advancements in Lipid Design for Lipid Nanoparticle Delivery Systems

  • Closing Remarks and Discussion